

**899 NORTH CAPITOL ST. NE – 2ND FLR.
WASHINGTON, DC 20002**

August 1, 2019

9:30am-11:30 am

OPEN SESSION AGENDA

Board of Pharmacy Mission Statement:

“To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians.”

CALL TO ORDER:

PRESIDING:

BOARD MEMBERSHIP/ATTENDANCE:

BOARD MEMBERS:		
	DR. TAMARA McCANTS, PHARM.D. R.PH CHAIRPERSON	
	MR. JAMES APPLEBY, R.PH VICE CHAIR	
	DR. BENJAMIN MILES, PHARM.D. R.PH	
	MR. ALAN FRIEDMAN, R.PH	
	DR. ASHLEE BOW, PHARM.D. R.PH	
	CHIKITA SANDERS, CONSUMER BOARD MEMBER	
STAFF:	SHAUNA WHITE, EXECUTIVE DIRECTOR	
	KARIN BARRON, HEALTH LICENSING SPECIALIST	
	LUANNE GREENAWAY, HEALTH LICENSING SPECIALIST	
LEGAL STAFF:	CARLA WILLIAMS, ASSISTANT GENERAL COUNSEL	
VISITORS:		

Open Session Agenda

Quorum:

Introduction:	<p>Honoring Dr. Daphne Bernard of her service as the DC Board of Pharmacy Chairperson.</p> <p>Introduction of the New DC Board of Pharmacy Chairperson, Dr. Tamara McCants and the New Pharmacist Board Member, Dr. Ashlee Bow</p>	
o801-O-01	<p><u>Approval of the Open Session Meeting Minutes</u></p> <p>June 6, 2019</p>	
<u>Consent Agenda</u>	None	
<u>Executive Director Report</u>	<p><u>Licensing Report</u></p> <p>Statistics Prescription Monitoring Program Update Opioid Strategic Plan NABP Updates Pharmacist CE Audit Report Recommendation for next CE Audit Public Health Priority Topic Suggestions</p>	
<u>Assistant General Counsel Report</u>		Carla Williams
o801-O-02	<p>Clinical Lab Practitioner Advisory Committee Updates</p> <p>(a) Clinical Laboratory Practitioners Amendment Act of 2014 B20-0289</p>	
o801-O-03	<p>Notice of Proposed Rulemaking-Public Health Priority Continuing Education Legislation</p> <p>The purpose of this rulemaking is to amend the continuing education requirements for pharmacy technicians, pharmacists, and pharmaceutical detailers to include continuing education in public health priorities as determined and amended from time to time by the Director.</p> <p>(a) Pharmacy Technicians (b) Pharmacists (c) Pharmaceutical Detailers</p>	

<u>Subcommittee Report</u>		
	<u>Legislative and Regulatory</u>	
o801-O-04	<p>Defending Access to Women’s Health Care Services Amendment Act of 2017</p> <ul style="list-style-type: none"> (a) Defending Access to Woman’s Health Care Services Congressional Review Emergency Declaration Resolution of 2018 (b) Drafted Regulations (c) Algorithm Flowchart (d) Self-Screening Questionnaire (e) Referral and Visit Summary When Birth Control is Prescribed (f) Referral and Visit Summary When Birth Control is Not Prescribed 	Dr. Benjamin Miles
o801-O-05	<p>Collaborative Practice Regulations</p> <p>The Board of Medicine reviewed the findings from the Collaborative Practice Subcommittee at their June meeting, and voted to approve the following categories as not needing approval by the Boards:</p> <ul style="list-style-type: none"> a. Parenteral Nutrition b. Vancomycin c. Aminoglycosides d. Phenytoin e. Anticoagulation/Warfarin f. Renal Dose Adjustments <p>For the other categories identified below, the Board of Medicine voted to continue discussion and research on the topics.</p> <ul style="list-style-type: none"> a. Pain Management (e.g., management of medication dosing) b. HIV c. Diabetes d. Hypertension e. Hyperlipidemia f. Depression <p>Additional suggestion for consideration is Smoking Cessation</p>	
o801-O-06	<u>Communications Subcommittee Report</u>	Dr. Shauna White
NABP E-Newsletter	<p><u>July 3, 2019</u></p> <p>After Reducing Prescription Opioid Availability, Counterfeits Are Now a Growing Problem, Op-Ed</p>	

	<p>PTCB Offers Streamlined Recertification Process for CPhTs via the NABP e-Profile</p> <p>FDA Issues Warning to Companies Selling Illegal Kratom Products via Social Media and Other Websites</p> <p>Four Mississippi Health Care Providers Indicted for Participation in Compounding Fraud Scheme</p> <p>DEA Hosts Industry Association Conference to Collaborate on Preventing Prescription Drug Abuse</p> <p><u>June 19, 2019</u></p> <p>Published Changes to USP General Chapters Will Become Official on December 1, 2019</p> <p>Study Estimates 300,000 Annual Child Fatalities Due to Counterfeit Medications</p> <p>US Marshals Seize Adulterated Dietary Supplements From Life Rising Corporation Due to Poor Manufacturing Practices</p> <p>Leading Expert in Counterfeit Medicines Rejoins PSM Board of Directors</p>	
<u>Matters for Board Consideration</u>		
o801-O-07	<p>Miranda G. Law, PharmD., BCPS Howard University-Request for Exemption/Exception for International Students that Participate in a Shadowing Opportunity</p> <p>During the June 2019 meeting, the Board moved to Invite the Dean/Professor of Howard University’s College of Pharmacy to the DC Board of Pharmacy’s August Monthly Meeting to discuss its Exemption/Exception request for International Students.</p> <p>(a) Letter of Request (b) Chapter 65 Title 17 DC Municipal Regulations for Pharmacists</p>	
<u>Public Comments</u>	<p>Opioid Symposium Presentation-Anthea V. Francis, Office of Continuing Professional Education Howard University College of Pharmacy</p> <ul style="list-style-type: none"> ▪ Share information about the grant ▪ Share details about the CE event that is being provided as a consequence of the grant funding ▪ Promote and highlight the value of this type of REMS programming being offered in the District of Columbia 	
Motion to Adjourn the Open Session	<p>“Madam Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following</p>	

	purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14)." (Roll Call Vote)	
--	--	--

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at __:__

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov.